JP2011502131A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502131A5
JP2011502131A5 JP2010531331A JP2010531331A JP2011502131A5 JP 2011502131 A5 JP2011502131 A5 JP 2011502131A5 JP 2010531331 A JP2010531331 A JP 2010531331A JP 2010531331 A JP2010531331 A JP 2010531331A JP 2011502131 A5 JP2011502131 A5 JP 2011502131A5
Authority
JP
Japan
Prior art keywords
trioxolane
dispiro
administered
scheduled
malaria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010531331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502131A (ja
JP5559057B2 (ja
Filing date
Publication date
Priority claimed from US11/930,606 external-priority patent/US8067620B2/en
Application filed filed Critical
Publication of JP2011502131A publication Critical patent/JP2011502131A/ja
Publication of JP2011502131A5 publication Critical patent/JP2011502131A5/ja
Application granted granted Critical
Publication of JP5559057B2 publication Critical patent/JP5559057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010531331A 2007-10-31 2008-10-29 ジスピロ1,2,4−トリオキソラン抗マラリア剤 Active JP5559057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/930,606 US8067620B2 (en) 2005-05-04 2007-10-31 Dispiro 1,2,4-trioxolane antimalarials
US11/930,606 2007-10-31
PCT/US2008/081579 WO2009058859A2 (en) 2007-10-31 2008-10-29 Dispiro 1,2,4-trioxolane antimalarials

Publications (3)

Publication Number Publication Date
JP2011502131A JP2011502131A (ja) 2011-01-20
JP2011502131A5 true JP2011502131A5 (enExample) 2011-12-15
JP5559057B2 JP5559057B2 (ja) 2014-07-23

Family

ID=40228026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531331A Active JP5559057B2 (ja) 2007-10-31 2008-10-29 ジスピロ1,2,4−トリオキソラン抗マラリア剤

Country Status (19)

Country Link
US (1) US8067620B2 (enExample)
EP (1) EP2203457B1 (enExample)
JP (1) JP5559057B2 (enExample)
KR (1) KR101588468B1 (enExample)
CN (1) CN101842377B (enExample)
AU (1) AU2008318819C1 (enExample)
BR (1) BRPI0818121B8 (enExample)
CA (1) CA2702256C (enExample)
CY (1) CY1115148T1 (enExample)
DK (1) DK2203457T3 (enExample)
ES (1) ES2466319T3 (enExample)
HR (1) HRP20140435T1 (enExample)
MX (1) MX2010004601A (enExample)
PL (1) PL2203457T3 (enExample)
PT (1) PT2203457E (enExample)
RU (1) RU2493159C2 (enExample)
SI (1) SI2203457T1 (enExample)
UA (1) UA99742C2 (enExample)
WO (1) WO2009058859A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2012106190A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
AU2013276702A1 (en) * 2012-06-13 2014-11-27 Medizinische Universitat Wien Amidophenoxypropanolamines
CA2937752C (en) 2014-02-14 2023-02-07 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
EP3309156A1 (en) 2016-10-13 2018-04-18 MMV Medicines for Malaria Venture New anti-malarial agents
BR112019006456A2 (pt) 2016-10-13 2019-06-25 Medicines For Malaria Venture Mmv diespiro 1,2,4-trioxolano, formulação farmacêutica, processo para a preparação de um derivado de diespiro 1,2,4-trioxolano, intermediário, e, método para prevenir e/ou tratar malária e esquistossomose ou um câncer.
WO2018213220A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Ozonides for treating or preventing virus infections
WO2019005977A1 (en) 2017-06-27 2019-01-03 The Regents Of The University Of California TRIOXOLANE AGENTS
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621062A (en) 1966-10-25 1971-11-16 Sterling Drug Inc 2-(8-cyclohexyloctanoyl or 7-cyclohexylheptanoyl)-1-naphthol
US3673222A (en) 1969-11-26 1972-06-27 Sydney Archer 2-(8-cyclohexyloctyl or 7-cyclohexylheptyl)-1,4-naphthoquinone and process for preparation and use thereof
US3682991A (en) 1970-10-19 1972-08-08 Sterling Drug Inc 3,3,5-trimethylcyclohexyl-alkyl-carboxylic acids
US4978678A (en) * 1986-11-20 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 12-halogenated forskolin derivatives
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4816478A (en) 1987-08-24 1989-03-28 Thornfeldt Carl R Treatment of acquired immunodeficiency syndrome
US5053342A (en) 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
US5270344A (en) 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
JP2867529B2 (ja) 1990-01-22 1999-03-08 三菱電機株式会社 投写型表示装置
US5216175A (en) 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5219880A (en) 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5510356A (en) 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
US5171676A (en) 1991-10-31 1992-12-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of introducing hydroxyl groups into artemisinin and its derivatives
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
BR9306816A (pt) 1992-07-28 1998-12-08 Procter & Gamble Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5780675A (en) 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5578637A (en) 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5817692A (en) 1995-11-22 1998-10-06 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5672624A (en) 1995-11-22 1997-09-30 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5932591A (en) 1996-12-02 1999-08-03 Johns Hopkins University C3 substituted trioxanes useful as antiparasitic drugs
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
CN101272777B (zh) * 2005-05-18 2013-01-30 兰贝克赛实验室有限公司 螺和二螺1,2,4-三氧戊环抗疟药的稳定剂型

Similar Documents

Publication Publication Date Title
US20230255995A1 (en) Nicotinyl Riboside Compounds and Their Uses
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2022553934A (ja) 薬学的製剤
EP3642214A2 (en) Nicotinamide riboside derivatives and their uses
JP2019522024A (ja) 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2017528494A (ja) sGC刺激剤
JP2017518334A5 (enExample)
JP2018518498A (ja) ケタミン経皮送達システム
JP2022087276A (ja) メマンチン経皮送達システム
KR20150093819A (ko) 약제 조성물
JP2009504763A5 (enExample)
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2012502047A5 (enExample)
US20200179415A1 (en) Highly active drug combination for treatment of hepatitis c virus
RU2010121919A (ru) Диспиро 1, 2, 4-триоксоланы как противомалярийные средства
WO2014027334A2 (es) Composicion farmacéutica oral en forma de microesferas y proceso de elaboración
RU2431502C2 (ru) Фармацевтические композиции для лечения сухости глаз
RU2621128C2 (ru) Фармацевтическая композиция для пролонгированного высвобождения триметазидина
JP2009513713A5 (enExample)
JP2021534160A5 (enExample)
JP7232932B2 (ja) Ws-635及び医学におけるその使用
JP2015143256A (ja) 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤
WO2025111482A1 (en) Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
CA3222959A1 (en) Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists